ALS clinical trial intelligence

Initiation of Long-term Home Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode During a Daytime Trial

Initiation of Long-term Home Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode During a Daytime Trial is a NA clinical asset sponsored by Marta Kaminska in Amyotrophic Lateral Sclerosis (ALS). SEO and diligence focus: Non-invasive home ventilation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28

An Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28 is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in Amyotrophic Lateral Sclerosis. SEO and diligence focus: BLZ945, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Amyotrophic Lateral Sclerosis

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial

Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial is a PHASE2 clinical asset sponsored by Dallas VA Medical Center in Amyotrophic Lateral Sclerosis (ALS). SEO and diligence focus: Antioxidants, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis

A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis is a PHASE1 clinical asset sponsored by Newron Sweden AB in Amyotrophic Lateral Sclerosis. SEO and diligence focus: sNN0029 infusion solution, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Amyotrophic Lateral Sclerosis

NYSCF Scientific Discovery Biobank

NYSCF Scientific Discovery Biobank is a registry-stage clinical asset sponsored by New York Stem Cell Foundation Research Institute in ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder. SEO and diligence focus: Biological Sample Collection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: ALS

Evaluation of a Mechanical Insufflation-exsufflation Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders: a Prospective, Randomized, Controlled, Multicenter Study

Evaluation of a Mechanical Insufflation-exsufflation Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders: a Prospective, Randomized, Controlled, Multicenter Study is a PHASE3 clinical asset sponsored by Assistance Publique - Hôpitaux de Paris in Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Neuromuscular Diseases. SEO and diligence focus: mechanical insufflation - exsufflation, Standard respiratory physiotherapy, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.

A Phase 1b/2 Study to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. is a PHASE1 clinical asset sponsored by Nura Bio in Amyotrophic Lateral Sclerosis (ALS). SEO and diligence focus: NB-4746 High dose, NB-4746 Low dose, Placebo, NB-4746 (Dose TBD), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

Myoelectric Devices for Restoration of Independent Arm Function in Children and Adults With Neurological Disease and Injury

The NuroSleeve study, sponsored by Thomas Jefferson University, aims to evaluate the efficacy of a novel powered arm brace combined with muscle stimulation for individuals with arm weakness or paralysis due to neurological conditions. The potential market for such devices is significant, given the prevalence of neurological disorders and the growing demand for assistive technologies that enhance independence in daily activities. If successful, this study could lead to the commercialization of the NuroSleeve, positioning it favorably against existing rehabilitation technologies. Competitive analysis should consider other myoelectric devices and rehabilitation solutions, as well as the regulatory landscape for medical devices in the U.S. and globally. Diligence implications include assessing the scalability of production, reimbursement pathways, and potential partnerships with rehabilitation centers and healthcare providers.

Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)

The trial conducted by Fondazione Salvatore Maugeri aims to evaluate the feasibility of a structured telesurveillance program combined with home cough assistance for ALS patients. Given the increasing prevalence of ALS and the need for innovative home care solutions, this program could represent a significant advancement in patient management, potentially reducing hospitalizations and improving quality of life. The market for ALS therapies and supportive care is growing, with increasing interest from both pharmaceutical companies and healthcare providers. The successful implementation of this program may enhance the competitive positioning of the sponsor in the ALS care landscape, particularly in telemedicine and home healthcare sectors. Diligence implications include assessing the scalability of the program and its cost-effectiveness compared to traditional care models.

Matched by conditions: Amyotrophic Lateral Sclerosis

Diaphragmatic Pacer Placement: Anesthetic Management (DP)

The Diaphragmatic Pacer (DP) represents a significant advancement in the management of patients with chronic respiratory failure due to SCI and ALS. By potentially reducing reliance on mechanical ventilation, the DP could lead to improved patient quality of life and decreased healthcare costs associated with prolonged mechanical ventilation. The market for respiratory support devices is growing, driven by an increasing prevalence of neuromuscular disorders. Competitive analysis indicates that while there are existing mechanical ventilation solutions, the unique application of diaphragmatic pacing positions the DP as a differentiated offering. Diligence should focus on the long-term efficacy and safety data, as well as reimbursement pathways for the device, which could influence market adoption.

Matched by conditions: Amyotrophic Lateral Sclerosis

Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

AB Science is currently conducting a Phase 3 clinical trial to evaluate the efficacy and safety of masitinib in combination with riluzole for the treatment of ALS. The market for ALS therapies is competitive, with riluzole being the current standard of care. If successful, masitinib could provide a novel therapeutic option that enhances the effects of riluzole, potentially capturing a significant share of the ALS treatment market. The trial is actively recruiting across multiple international sites, indicating robust interest and investment in this therapeutic area. The outcome of this trial could influence AB Science's market positioning and valuation significantly, especially if the results demonstrate a statistically significant improvement in ALSFRS-R scores compared to placebo.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Apellis Pharmaceuticals' pegcetacoplan (APL-2) was evaluated in a Phase 2 clinical trial for amyotrophic lateral sclerosis (ALS). The study aimed to assess its efficacy and safety over 24 months. Despite the potential of pegcetacoplan as a complement inhibitor, the trial was terminated after failing to meet primary and key secondary endpoints at Week 52. This outcome raises concerns regarding the commercial viability of pegcetacoplan in the ALS market, which is characterized by limited treatment options and high unmet medical need. The competitive landscape includes established therapies like riluzole and edaravone, as well as emerging therapies targeting similar pathways. Investors and stakeholders should consider the implications of this trial's results on Apellis' pipeline and future strategic direction.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Pilot Study to Evaluate the Use of the MN4000 for Treatment of Cystic Fibrosis (CF) and Motor Neuron Disease (MND) Patients in the Home Setting

The MN4000, marketed as The MetaNeb® System, is a Class II medical device cleared for home use in patients with Cystic Fibrosis (CF) and Motor Neuron Disease (MND). The pilot study demonstrated feasibility in a home setting, with a focus on patient satisfaction and adherence. Given the increasing prevalence of CF and MND, the device addresses a significant market need for effective home-based respiratory therapies. Competitive positioning may be strengthened by positive patient feedback and adherence metrics, which could support future regulatory submissions for expanded indications or larger-scale studies. Diligence should focus on reimbursement pathways and potential partnerships with healthcare providers for broader adoption.

Matched by conditions: Motor Neuron Disease

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-SOD1 in Adult Patients With Amyotrophic Lateral Sclerosis Harboring a Superoxide Dismutase-1 Mutation Considered to be Causative of Amyotrophic Lateral Sclerosis

ARO-SOD1, developed by Arrowhead Pharmaceuticals, targets a specific genetic mutation (SOD1) implicated in ALS, a progressive neurodegenerative disease with significant unmet medical need. The market for ALS therapies is expanding, particularly for genetic forms of the disease, with increasing interest from both patients and investors. However, the trial has been withdrawn due to a company business decision, which may indicate strategic realignment or resource allocation issues. This withdrawal could impact Arrowhead's competitive positioning in the ALS space, especially against other emerging therapies targeting SOD1 and other genetic mutations. Diligence implications include a need to assess the company's pipeline and financial health post-withdrawal.

Matched by conditions: Amyotrophic Lateral Sclerosis

Single Neuron Population Dynamics in Human Speech Motor Cortex for a Speech Prosthesis

The BrainGate2 Neural Interface System aims to provide a novel solution for individuals with severe speech impairments, particularly those suffering from conditions like ALS. The potential market includes a significant population of patients with anarthria and dysarthria, representing a niche yet impactful segment within the assistive technology landscape. The competitive landscape includes other neuroprosthetic devices, but the unique focus on speech restoration may offer a distinct advantage. Successful outcomes could lead to partnerships with rehabilitation centers and technology firms, enhancing market penetration. Diligence implications include assessing regulatory pathways and reimbursement strategies, given the unapproved status of the device.

Matched by conditions: Amyotrophic Lateral Sclerosis

Evaluation of Microglial Activation Using the PET Imaging Ligand [18F]PBR06 in Patients With Amyotrophic Lateral Sclerosis Compared to Healthy Volunteers

The clinical trial conducted by Molecular NeuroImaging aims to assess microglial activation in patients with Amyotrophic Lateral Sclerosis (ALS) using the PET imaging ligand [18F]PBR06. Given the increasing prevalence of neurodegenerative diseases and the need for effective diagnostic tools, this study positions [18F]PBR06 as a potential biomarker for ALS, which could enhance patient stratification and monitoring. The market for ALS therapeutics and diagnostics is growing, with a focus on innovative imaging techniques. The results of this trial may provide a competitive edge in the neuroimaging market, particularly for companies developing ALS therapies or diagnostics. Diligence should focus on the regulatory pathway for [18F]PBR06 and potential partnerships with pharmaceutical companies for further development.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Phase 1, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adult Participants With Amyotrophic Lateral Sclerosis

BIIB100, developed by Biogen, is currently in Phase 1 clinical trials for the treatment of amyotrophic lateral sclerosis (ALS). The market for ALS therapies is growing, driven by increasing awareness and diagnosis rates, alongside a limited number of effective treatment options. The competitive landscape includes established therapies like riluzole and edaravone, but there remains a significant unmet need for novel treatments that can improve patient outcomes. Successful completion of this trial could position Biogen favorably in the ALS market, potentially leading to partnerships or acquisition interest from larger pharmaceutical companies. Diligence should focus on the safety and tolerability profile of BIIB100, as well as its pharmacokinetic characteristics, which will be critical for future development stages.

A Phase 2B/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tazbentetol in Participants With Amyotrophic Lateral Sclerosis (ALS)

Spinogenix is advancing tazbentetol through a Phase 2B/3 clinical trial aimed at addressing the unmet medical need in ALS, a progressive neurodegenerative disease with limited treatment options. The study's dual-phase design allows for adaptive dosing based on Phase 2 results, potentially enhancing the drug's market viability. The ALS market is characterized by high demand for effective therapies, with a growing focus on innovative treatments. Competitive landscape analysis indicates that successful outcomes could position Spinogenix favorably against existing therapies, particularly if tazbentetol demonstrates significant efficacy and safety. Diligence considerations should include the robustness of trial design, regulatory pathways, and potential partnerships for commercialization.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease

The trial is sponsored by Collaborative Medicinal Development Pty Limited and aims to evaluate the efficacy and tolerability of Cu(II)ATSM in patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). The ALS market is characterized by limited treatment options, primarily dominated by riluzole and edaravone, which highlights a significant unmet need for novel therapies. Successful outcomes from this trial could position Cu(II)ATSM as a competitive therapeutic option, potentially expanding the treatment landscape for ALS/MND. The estimated enrollment of 80 patients suggests a focused study, which may facilitate quicker data analysis and market entry if successful. However, the overall status of the trial remains 'UNKNOWN' as of the last update, necessitating close monitoring of recruitment and results.

An In-home Study of Brain Computer Interfaces

The University of Michigan's study on brain-computer interfaces (BCIs) aims to enhance the independence of individuals with severe paralysis, particularly those with Amyotrophic Lateral Sclerosis (ALS). The market for assistive technologies is growing, driven by an increasing aging population and rising prevalence of neurological disorders. The unique nature of this BCI technology, which allows users to control wheelchairs and communicate, positions it competitively against existing assistive devices. However, the limited enrollment (only one participant) raises concerns regarding scalability and market viability. Further exploration of user experience and technology refinement will be critical for commercial success.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis

The study evaluates Myobloc's efficacy in treating sialorrhea in ALS patients, a condition with limited treatment options. If successful, this could position Myobloc as a preferred therapy in a niche market, potentially expanding its use beyond existing indications. The ALS market is characterized by high unmet needs, and successful outcomes could lead to increased adoption and market share. Competitive landscape includes other botulinum toxin products and anticholinergic medications, but Myobloc's unique mechanism may offer advantages in refractory cases. Diligence should focus on the safety profile and long-term effects, as well as potential regulatory hurdles for expanded indications.

Matched by conditions: Amyotrophic Lateral Sclerosis

An Open-label, Single-center, 6-month Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

The trial of Theracurmin for ALS represents a novel approach in a market characterized by limited effective treatments for this progressive neurodegenerative disease. The ALS market is projected to grow significantly due to increasing awareness and diagnosis rates. If Theracurmin demonstrates efficacy, it could position itself as a complementary therapy alongside existing treatments, enhancing patient quality of life. Competitive analysis indicates that while there are several investigational therapies, few focus on dietary supplements like Theracurmin, potentially offering a unique market niche. Diligence should focus on regulatory pathways, reimbursement strategies, and the potential for expanded indications based on microbiome analysis outcomes.

Matched by conditions: Amyotrophic Lateral Sclerosis

Imaging Myelin Injury in Amyotrophic Lateral Sclerosis (ALS)

The study, sponsored by Johns Hopkins University, aimed to explore the potential of 7 Tesla MRI as a diagnostic tool for assessing myelin injury in ALS patients. Although the trial was withdrawn, the insights gained could inform future research and development in ALS diagnostics. The ALS market is characterized by a growing demand for innovative diagnostic techniques, particularly those that can predict disease progression. Companies focusing on neurodegenerative diseases may find strategic opportunities in developing imaging technologies or biomarkers that correlate with clinical outcomes, especially as the ALS patient population continues to seek effective management options.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Tofersen (BIIB067) is being evaluated in a Phase 3 trial for its efficacy in presymptomatic adults carrying SOD1 mutations, a significant genetic contributor to amyotrophic lateral sclerosis (ALS). The market for ALS therapies is expanding, with increasing interest in genetic and targeted treatments. The trial's focus on presymptomatic patients may position Tofersen as a first-in-class therapy, potentially leading to a competitive advantage in a niche segment of the ALS market. The successful outcome of this trial could enhance Biogen's portfolio and provide a significant revenue stream, particularly given the unmet medical need in this patient population. However, the competitive landscape includes existing ALS therapies like riluzole and edaravone, as well as emerging gene therapies, necessitating careful monitoring of market dynamics and competitor developments.

A Pilot Study Assessing a New Eye-writing Device Allowing Cursive Writing With Smooth Pursuit Eye Movements in Subjects With ALS

The Eye On Line (EOL) device represents a novel approach to assist ALS patients in communication, addressing a significant unmet need in this patient population. The market for assistive communication devices is growing, driven by the increasing prevalence of neurodegenerative diseases. The EOL device's unique mechanism of utilizing smooth pursuit eye movements for writing could differentiate it from existing solutions, potentially capturing a niche market. Competitive analysis indicates a limited number of similar devices, suggesting a favorable position for EOL if proven effective. Diligence should focus on regulatory pathways, reimbursement strategies, and partnerships with ALS advocacy groups to enhance market penetration.

Matched by conditions: Amyotrophic Lateral Sclerosis

Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS)

The clinical trial for mexiletine in sporadic amyotrophic lateral sclerosis (SALS) aims to explore its potential to reduce cortical hyperexcitability and slow disease progression. Given the lack of effective treatments for ALS, a successful outcome could position mexiletine as a novel therapeutic option in a market with significant unmet needs. The competitive landscape includes existing therapies like riluzole and edaravone, but mexiletine's unique mechanism may provide a differentiated profile. Diligence should focus on the safety profile, potential market entry barriers, and the regulatory pathway, especially considering mexiletine's prior FDA approval for other indications.

Matched by conditions: Sporadic Amyotrophic Lateral Sclerosis

A Multi-Center, Randomized, Double-Blind Placebo Controlled Multiple-Ascending Dose Study to Evaluate the Safety and Tolerability of QRL-201 in Amyotrophic Lateral Sclerosis, Followed by an Open-Label Extended Dosing Period

QurAlis Corporation's QRL-201 is currently in a Phase 1 clinical trial aimed at evaluating its safety and tolerability in patients with Amyotrophic Lateral Sclerosis (ALS). The trial is designed as a multi-center, randomized, double-blind, placebo-controlled study, which is critical for establishing the drug's potential in a competitive landscape dominated by limited effective therapies for ALS. The ALS market is characterized by high unmet medical needs, with a growing demand for innovative treatments. If successful, QRL-201 could position QurAlis favorably against existing therapies, particularly those targeting genetic forms of ALS, such as therapies for SOD1 and C9orf72 mutations. The trial's design includes an open-label extended dosing period, which may facilitate ongoing patient engagement and data collection, enhancing the asset's value proposition.

Exploratory Study on the Effects of Lung Insufflation Capacity Training Using the LIC Trainer in Patients With Amyotrophic Lateral Sclerosis: A Single-Center Prospective Interventional Study

This exploratory study, sponsored by the National Center of Neurology and Psychiatry in Japan, investigates the potential of the LIC Trainer device to improve respiratory function and prolong survival in ALS patients. The market for ALS therapies is expanding, with a growing focus on supportive care and rehabilitation strategies. If successful, the findings could position the LIC Trainer as a pivotal tool in respiratory rehabilitation for ALS, potentially leading to commercial opportunities in both Japan and globally. The absence of a control group necessitates careful interpretation of results, and further studies may be required to substantiate efficacy claims. Competitive implications include the need to monitor other emerging therapies targeting respiratory function in ALS, as well as alternative rehabilitation devices.

A Single Patient Treatment Protocol for Autologous Mesenchymal Stem Cell Intraspinal Therapy in Amyotrophic Lateral Sclerosis (ALS)

The clinical trial conducted by Mayo Clinic represents an exploratory approach to ALS treatment through autologous mesenchymal stem cell therapy. Given the progressive nature of ALS and the limited treatment options currently available, this trial could position the sponsor favorably within a niche market focused on neurodegenerative diseases. The successful demonstration of safety and potential efficacy could attract interest from larger biopharmaceutical companies for partnerships or acquisition, especially in light of the growing demand for innovative therapies in ALS. Competitive implications include the need to monitor other ongoing trials in stem cell therapies for ALS, as well as alternative treatment modalities that may emerge. Diligence considerations should focus on the regulatory landscape for stem cell therapies and the potential for reimbursement challenges in the U.S. healthcare system.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS)

The clinical trial for mexiletine in patients with sporadic Amyotrophic Lateral Sclerosis (SALS) aims to evaluate the safety and efficacy of two dosing regimens (300 mg and 900 mg) compared to a placebo. Given the lack of effective treatments for ALS, a successful outcome could position mexiletine as a novel therapeutic option in a market with significant unmet needs. The ALS market is characterized by limited competition, primarily dominated by riluzole and edaravone, which may provide a favorable environment for mexiletine if proven effective. The trial's completion and subsequent data could attract interest from larger pharmaceutical companies for potential partnerships or acquisitions, enhancing the asset's commercial viability.

Matched by conditions: Sporadic Amyotrophic Lateral Sclerosis

An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)

Flex Pharma, Inc. initiated the FLX-787-107 study to evaluate the safety and efficacy of FLX-787-ODT for treating fasciculations in ALS patients. The study's termination indicates a significant setback in the development of this formulation, potentially impacting Flex Pharma's market position in the neuromuscular disorder space. The ALS market is characterized by limited treatment options, and any effective therapy could capture substantial market share. However, the cessation of this study raises concerns regarding the viability of FLX-787-ODT and may necessitate a reevaluation of Flex Pharma's pipeline and strategic direction. Competitors in the ALS treatment landscape may benefit from this development halt, as they could accelerate their own programs to fill the unmet need.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Two-Part Phase 3b Randomized, Double-Blind, Placebo-Controlled, Followed by Open-Label Extension, Multicenter Study of the Efficacy and Safety of MSC-NTF (NurOwn) in Participants With With Early Symptomatic and Moderate Disease Presentation in Amyotrophic Lateral Sclerosis (ALS)

Brainstorm Cell Therapeutics is advancing its investigational product, NurOwn (Debamestrocel), through a Phase 3b trial targeting early symptomatic and moderate presentation of Amyotrophic Lateral Sclerosis (ALS). The trial's dual-part design, including a randomized placebo-controlled phase followed by an open-label extension, aims to establish both efficacy and safety. If successful, NurOwn could capture a significant share of the ALS treatment market, which is currently limited in options. The competitive landscape includes other therapies in development, but few focus on stem cell-based approaches. The trial's outcomes will be critical for investor confidence and potential partnerships, especially given the unmet medical need in ALS.

Safety and Tolerability of the Ketogenic Diet in ALS

The trial, sponsored by Johns Hopkins University, aimed to evaluate the safety and tolerability of the ketogenic diet in ALS patients with gastrostomy tubes. Although the study has been terminated, it highlights the growing interest in dietary interventions for neurodegenerative diseases, particularly ALS. The market for ALS treatments is competitive, with existing therapies like Riluzole and emerging gene therapies. Companies exploring dietary supplements or nutritional interventions may find strategic opportunities, especially if safety data supports further investigation. Diligence should focus on the regulatory landscape surrounding dietary supplements and the potential for partnerships with academic institutions.

Matched by conditions: Amyotrophic Lateral Sclerosis

An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner

MCI-186 (edaravone) is being evaluated for its efficacy in treating patients with Amyotrophic Lateral Sclerosis (ALS) classified as severity III. The ALS market is characterized by limited treatment options, with edaravone being one of the few approved therapies. The completion of this trial could enhance Tanabe Pharma Corporation's position in the ALS market, particularly if positive results are obtained. Given the increasing prevalence of ALS and the demand for effective therapies, successful outcomes could lead to significant commercial opportunities. However, the competitive landscape includes other investigational therapies, necessitating a robust differentiation strategy.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

Real World Testing of a Brain-Computer Interface to Operate a Commercial Augmentative and Alternative Communication System

The University of Pittsburgh's clinical trial focuses on the innovative application of BCI technology to enhance communication for individuals with severe disabilities, such as ALS, TBI, and cerebral palsy. The market for AAC devices is expanding, driven by increasing awareness and demand for assistive technologies. This study's findings could position the University of Pittsburgh as a leader in the AAC-BCI space, potentially attracting partnerships or funding from healthcare providers and technology developers. Competitive implications include the need to monitor existing AAC solutions and emerging BCI technologies that may enter the market. Diligence considerations should include assessing the scalability of the technology and its integration into existing healthcare frameworks.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. is advancing a Phase I clinical trial for XS228CN, a novel therapy utilizing iPSC-derived motor neuron progenitor cells aimed at treating ALS. The ALS market is characterized by a high unmet need, with limited effective therapies currently available. The successful demonstration of safety and preliminary efficacy could position XS228CN as a significant player in the ALS treatment landscape, potentially attracting partnerships or acquisition interest from larger biopharmaceutical companies. Given the trial's focus on a debilitating and progressive disease, positive outcomes could enhance the company's valuation and market presence.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)

ONO-2506PO is currently undergoing a Phase II multi-centre extension study to evaluate its long-term safety in ALS patients. Given the increasing prevalence of ALS and the limited treatment options available, this study positions Ono Pharmaceutical Co., Ltd. to potentially capture a significant share of the ALS market if ONO-2506PO demonstrates favorable safety and efficacy profiles. The competitive landscape includes existing therapies such as Riluzole and Edaravone, but there remains a substantial unmet need for novel treatments. Diligence should focus on the outcomes of this study and any potential regulatory pathways that may expedite approval.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

A Phase I Trial to Evaluate Safety and Tolerability of Abatacept Followed by Subcutaneous Interleukin-2 Administration in Patients With Amyotrophic Lateral Sclerosis

The Phase 1 trial, sponsored by The Methodist Hospital Research Institute, investigates the safety and tolerability of a combination therapy involving abatacept (Orencia) and subcutaneous IL-2 in ALS patients. Given the urgent need for effective treatments in ALS, which currently has limited therapeutic options, this trial could position the sponsor favorably within the niche ALS market. If successful, the findings may lead to further development and potential commercialization of this combination therapy, addressing a significant unmet medical need. Competitive implications include potential partnerships or licensing opportunities, particularly with companies focused on immunotherapy and neurodegenerative diseases. Diligence should focus on regulatory pathways and reimbursement strategies for ALS therapies.

Matched by conditions: Amyotrophic Lateral Sclerosis

P300 Brain Computer Interface Keyboard to Operate Assistive Technology

The P300 Brain Computer Interface Keyboard study, sponsored by the University of Michigan, aims to develop a BCI that enables individuals with paralysis to operate technology using brain signals. This innovative approach addresses a significant market need for assistive technologies, particularly for conditions such as Amyotrophic Lateral Sclerosis, spinal cord injuries, and other neuromuscular diseases. The successful development and commercialization of this technology could position the University of Michigan as a leader in the assistive technology market, which is projected to grow significantly due to increasing demand for adaptive devices. Competitive implications include potential partnerships with technology companies specializing in assistive devices and software, as well as the need to navigate existing patents in the BCI space to ensure freedom-to-operate.

Matched by conditions: Amyotrophic Lateral Sclerosis

An Open-label Single Center, Single Participant Study of an Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis (ALS) Due to CHCHD10 Gene Mutation

The n-Lorem Foundation is sponsoring a personalized antisense oligonucleotide (ASO) treatment targeting a specific genetic mutation (CHCHD10) in a single ALS patient. This study represents a novel approach to precision medicine in ALS, potentially positioning the foundation as a pioneer in the development of targeted therapies for rare genetic forms of the disease. The market for ALS treatments is competitive, with several therapies in development, but the personalized nature of this approach may differentiate it from existing options. Successful outcomes could lead to broader applications of ASO therapies in ALS and other genetic disorders, enhancing the foundation's strategic partnerships and funding opportunities.

Matched by conditions: Amyotrophic Lateral Sclerosis

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

The clinical trial sponsored by Johns Hopkins University aims to explore the feasibility of psilocybin therapy for patients with Amyotrophic Lateral Sclerosis (ALS) who exhibit depressive symptoms. Given the increasing interest in psychedelic therapies, this study positions itself in a niche market that addresses both ALS and mental health, potentially opening avenues for novel treatment options. The competitive landscape includes other psychedelic compounds being investigated for various psychiatric conditions, but the specific focus on ALS may provide a unique market opportunity. Diligence considerations should include regulatory pathways, potential partnerships with biotech firms, and the evolving public perception of psychedelics in therapeutic contexts.

Matched by conditions: Amyotrophic Lateral Sclerosis

Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole

TRO19622, developed by Hoffmann-La Roche, is positioned as an add-on therapy to the existing ALS treatment, Riluzole. The ALS market is characterized by limited treatment options, with Riluzole being the only approved drug that has shown a modest effect on survival. The success of TRO19622 could provide a significant competitive advantage, addressing a critical unmet need in ALS therapy. The trial's completion and subsequent results may enhance Roche's portfolio in neurology, potentially leading to market exclusivity if the product demonstrates efficacy and safety. Given the high incidence of ALS and the increasing focus on neurodegenerative diseases, the commercial prospects appear promising, contingent upon positive trial outcomes.

Amyotrophic Lateral Sclerosis: a New Paradigm

The completed observational study titled 'Amyotrophic Lateral Sclerosis: a New Paradigm' focuses on the epidemiological and genetic characterization of ALS patients in a region of high prevalence in Portugal. Given the increasing incidence of ALS, particularly with bulbar involvement, there is a significant market opportunity for novel therapeutic interventions targeting genetic and environmental risk factors. The study's findings could inform future drug development and positioning within the ALS treatment landscape, which is currently limited by the lack of effective therapies. Companies focusing on genetic research and personalized medicine may find strategic partnerships or acquisition opportunities in this area. Additionally, the high prevalence of ALS in the studied region may attract interest from pharmaceutical companies looking to conduct further research or clinical trials.

Matched by conditions: Amyotrophic Lateral Sclerosis

Efficacy and Safety of Nitrazine in the Treatment of Amyotrophic Lateral Sclerosis: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study

The clinical trial for Nitroketazine, sponsored by Peking University Third Hospital, aims to evaluate the efficacy and safety of this treatment in ALS patients. With an estimated enrollment of 150 patients, the study is currently recruiting and is designed as a multicenter, randomized, double-blind, placebo-controlled trial. The ALS market is characterized by a high unmet need, with limited treatment options currently available. Successful outcomes could position Nitroketazine as a significant player in the ALS treatment landscape, potentially leading to market exclusivity if patent protections are secured. The competitive landscape includes existing therapies such as Riluzole and Edaravone, which may face challenges if Nitroketazine demonstrates superior efficacy or safety profiles.

Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations

The trial investigates the safety and efficacy of L-carnitine in ALS patients with specific CHCHD10 mutations. Given the limited treatment options for ALS, a successful outcome could position L-carnitine as a novel therapeutic approach, potentially expanding its market presence in neuromuscular disorders. The competitive landscape includes existing ALS therapies, but the specificity to CHCHD10 mutations may provide a unique market niche. Diligence should focus on the trial's safety profile and efficacy data, as well as potential regulatory pathways for approval in this specific patient population.

Matched by conditions: Amyotrophic Lateral Sclerosis (ALS)

Using Behavioral Economics and Implementation Science to Advance the Use of Genomic Medicine Utilizing an EHR Infrastructure Across a Diverse Health System

The University of Pennsylvania's clinical trial aims to innovate the implementation of genomic medicine by utilizing behavioral economics and advanced EHR systems. This approach targets a growing market for genetic testing, particularly as indications expand and the clinical utility of genetic results becomes increasingly recognized. The trial's focus on non-geneticist clinician and patient nudges positions it uniquely within the competitive landscape, potentially leading to improved patient outcomes and increased adoption of genetic testing across diverse health systems. The findings could influence reimbursement strategies and policy-making in genomic medicine, presenting opportunities for partnerships with EHR vendors and genetic testing laboratories.

Matched by conditions: ALS

A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Single and Multiple Dose Escalation Study in Healthy Volunteers and an Expansion Cohort in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302

Spinogenix is advancing SPG302 through a Phase 1/2a clinical trial aimed at assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and ALS patients. The ALS market is characterized by a high unmet need, with limited effective therapies currently available. Successful outcomes from this trial could position SPG302 as a novel treatment option, potentially capturing significant market share in a competitive landscape dominated by established therapies such as Riluzole and Edaravone. The collaboration with Novotech for trial execution enhances operational capabilities, while the completion of the trial by mid-2025 aligns with strategic timelines for potential market entry. Diligence should focus on the robustness of safety data and the drug's mechanism of action to ensure differentiation from existing therapies.

Exploratory Evaluation of [11C]MPC6827 Pharmacokinetics With Positron Emission Tomography (PET)

The exploratory study of [11C]MPC6827 represents a significant step in the development of diagnostic imaging for neurodegenerative diseases such as Alzheimer's Disease and ALS. Given the increasing prevalence of these conditions, the potential market for effective diagnostic tools is substantial. The results of this study could position [11C]MPC6827 as a novel imaging agent, enhancing the ability to visualize microtubule changes associated with these diseases. Competitive implications include the need to monitor other emerging imaging agents targeting similar pathways. Diligence should focus on the regulatory pathway and potential partnerships for further development and commercialization.

Matched by conditions: Amyotrophic Lateral Sclerosis

Impact of Nuedexta on Bulbar Physiology and Function in ALS

Nuedexta is already FDA-approved for pseudobulbar affect in ALS patients, but this study aims to provide evidence for its efficacy in improving bulbar functions such as speech and swallowing. The potential for expanded indications could enhance market positioning against competitors targeting ALS symptom management. Given the increasing prevalence of ALS and the limited treatment options available, successful outcomes may lead to significant commercial opportunities. Companies should conduct thorough diligence on the competitive landscape, particularly focusing on emerging therapies that address bulbar dysfunction.

Matched by conditions: Amyotrophic Lateral Sclerosis

Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients

Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients is a PHASE1 clinical asset sponsored by Alzahra Hospital, Iran in Amyotrophic Lateral Sclerosis. SEO and diligence focus: mesenchymal stem cell, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by conditions: Amyotrophic Lateral Sclerosis

Cistanche Total Glycosides Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response

Cistanche Total Glycosides (CTG) is being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disease with limited treatment options. Currently, riluzole is the only FDA-approved drug for ALS, highlighting a significant unmet need in the market. If CTG demonstrates efficacy in this randomized controlled trial, it could position itself as a novel therapeutic option, potentially capturing market share in a niche but critical segment. The trial's outcomes may also attract interest from investors and partners looking to expand their portfolios in neurodegenerative diseases, particularly given the increasing prevalence of ALS and the demand for innovative treatments.

Matched by conditions: Amyotrophic Lateral Sclerosis

Evaluation of the Effect of Respiratory Physiotherapy by Mechanical In-exsufflator on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis: A Pilot Study

This pilot study, sponsored by the University Hospital of Toulouse, aims to evaluate the efficacy of the Mechanical In-Exsufflator (MIE) in improving respiratory function in patients with Amyotrophic Lateral Sclerosis (ALS). Given the lack of curative treatments for ALS, this study could position MIE as a supportive therapeutic device in respiratory management, potentially enhancing patient quality of life. The market for ALS management is growing, with increasing focus on supportive therapies. The results of this study may influence future reimbursement policies and market access strategies for MIE devices in Europe and beyond. Competitive implications include the need to monitor other respiratory support devices and therapies targeting ALS and similar neurodegenerative conditions.

Matched by conditions: Amyotrophic Lateral Sclerosis

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

PathMaker Neurosystems Inc. is advancing the MyoRegulator® device through the CALM study, targeting the ALS market, which currently has approximately 30,000 patients in the U.S. and 5,000 new diagnoses annually. The study aims to establish preliminary safety and efficacy data, which could position the MyoRegulator® as a novel treatment option in a market with limited effective therapies. The device's non-invasive nature may appeal to patients and healthcare providers, potentially enhancing adoption rates. However, the competitive landscape includes established therapies like Riluzole and Edaravone, which may pose challenges in market penetration. The successful completion of this study could pave the way for a larger pivotal trial, attracting interest from investors and collaborators, particularly given the involvement of the U.S. Department of Defense as a collaborator.

Matched by conditions: ALS - Amyotrophic Lateral Sclerosis

A Single-center, Open-label Clinical Study to Evaluate the Efficacy and Safety of Low-dose IL-2 in the Treatment of Immune-associated ALS Syndrome

The ongoing clinical trial at Peking University Third Hospital aims to assess the efficacy and safety of low-dose IL-2 in treating immune-associated ALS syndrome. Given the limited treatment options available for ALS, a successful outcome could position IL-2 as a novel therapeutic approach, potentially capturing a significant share of the ALS treatment market. The trial's focus on immune-mediated variants of ALS, such as multifocal motor neuropathy and Lewis-Sumner syndrome, may also broaden the addressable patient population. Competitive analysis indicates that while several therapies are in development for ALS, few specifically target immune-related mechanisms, which could provide a unique market advantage. Diligence should focus on the trial's recruitment progress and the robustness of safety and efficacy data as it becomes available.

Matched by conditions: Amyotrophic Lateral Sclerosis

A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)

The pilot trial of Triheptanoin for ALS represents a potential breakthrough in the treatment of a disease with significant unmet medical need. Given the limited therapeutic options currently available for ALS, which primarily focus on symptom management rather than disease modification, Triheptanoin could carve out a niche in the market if proven effective. The collaboration with Ultragenyx Pharmaceutical Inc suggests a strategic partnership that may enhance development capabilities and market access. The trial's completion and forthcoming results could influence investor interest and competitive positioning within the neurodegenerative disease space, particularly against existing therapies like Riluzole and Radicava.

Matched by conditions: ALS

High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial

The multicenter randomized controlled trial aims to evaluate the efficacy of HD-tDCS in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease with significant unmet medical needs. The trial's focus on respiratory function and disease progression positions it strategically within the ALS treatment landscape, which currently lacks effective therapies. If successful, this intervention could provide a novel non-invasive treatment option, potentially capturing market share in a niche but critical segment of neuromodulation therapies. The trial is sponsored by Universidade Federal do Rio Grande do Norte, indicating a strong academic backing, which may enhance credibility and attract future partnerships or funding opportunities. Competitive implications include the need to monitor other neuromodulation approaches and therapies targeting ALS, as well as the broader market for neurostimulation devices.

An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Clene Nanomedicine's CNM-Au8 is currently in an open-label extension phase following a Phase 2 randomized, double-blind, placebo-controlled trial for early symptomatic Amyotrophic Lateral Sclerosis (ALS). The market for ALS therapies is expanding, with a growing demand for innovative treatments that can slow disease progression. The successful completion of this trial could position Clene favorably against competitors in the neurodegenerative space, particularly as there are limited effective therapies for ALS. The open-label extension allows for continued patient engagement and data collection, potentially enhancing the drug's profile and supporting future regulatory submissions.

Matched by conditions: Amyotrophic Lateral Sclerosis